Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Oncol Rep. 2010 Aug;24(2):563–569. doi: 10.3892/or_00000893

Figure 2.

Figure 2

Inhibition of COMT activity enhances proteasome inhibition and apoptosis induction by (-)-EGCG in breast cancer cells. MDA-MB-231 cells were treated with either 10 μM of the COMT inhibitor (DNC), 50 μM of (-)-EGCG, or a co-treatment with both DNC and (-)-EGCG for 24 h, followed by measuring COMT activity (A), proteasomal chymotrypsin (CT)-like activity (B), caspase-3/-7 activation (C), cellular morphological changes (D), and Hoechst nuclear staining (E). DMSO was used as solvent control. bars, SD; *p<0.05; **p<0.01. Magnification, x40.